Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate August 24, 2022
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer June 23, 2022
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports June 14, 2022
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses April 6, 2022
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1 March 22, 2022
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 March 10, 2022
Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript March 3, 2022
